Evidence map›Paper›PMID 27182558›Full record

ArticleJCI insight2016

Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors.

Heike E Daldrup-Link, Suchismita Mohanty, Celina Ansari, Olga Lenkov, Aubie Shaw, Ken Ito, Su Hyun Hong, Matthias Hoffmann, Laura Pisani, Nancy Boudreau and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. A Novel Theranostic Strategy forMolecular cancer therapeutics · 2017
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Heike E Daldrup-LinkDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Suchismita MohantyDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Celina AnsariDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Olga LenkovDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Aubie ShawDepartment of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Ken ItoDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Su Hyun HongDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Matthias HoffmannDepartment of Dermatology, Venereology and Allergology, Goethe University, Frankfurt, Germany.
Laura PisaniDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA.
Nancy BoudreauDepartment of Surgery, UCSF, San Francisco, California, USA.
Sanjiv Sam GambhirDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, USA; Department of Bioengineering, Stanford University, Stanford, California, USA; Department of Materials Science and Engineering, Stanford University, Stanford, California, USA.
Lisa M CoussensDepartment of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Oregon Health & Science University · USGoethe University Frankfurt · DEStanford University · USUniversity of California, San Francisco · US

Funding

Personalized Whole Body Staging for Children with Cancer: A Solution to the Conundrum of Long-Term Side Effects from CT and PET/CT ScansR01HD081123 · NICHD · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2015 to 2019
$2.5M
Leukocyte Biomarkers for Predicting Human Breast Cancer OutcomesU54CA163123 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M., KRUMMEL, MATTHEW F · 2011 to 2015
$2.0M
Regulating the Immune Microenvironment in Breast CancerR01CA155331 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M. · 2011 to 2015
$1.6M
Improved Drug Delivery to Tumors Using Novel Tissue Perfusion ApproachesR01CA140943 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOUDREAU, NANCY JOAN, COUSSENS, LISA M. · 2009 to 2012
$1.0M
Structural Analysis of Macromolecular Complexes by HighZ01BC010412 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MILNE, JACQUELINE · 2000 to 2008
$575k
Development of Novel Activatable Theranostic Nanoparticles for combined Cancer MRR21CA176519 · NCI · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH, RAO, JIANGHONG · 2014 to 2015
$403k
Imaging Tumor Associated Macrophages in Bone SarcomasR21CA190196 · NCI · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2016 to 2017
$378k
Intramural NIH HHS Z01 BC010412NCI NIH HHS R01 CA140943NCI NIH HHS R01 CA155331NCI NIH HHS R21 CA176519NCI NIH HHS R21 CA190196NCI NIH HHS U54 CA163123NICHD NIH HHS R01 HD081123
6 · The paper itself

Abstract

Limited transendothelial permeability across tumor microvessels represents a significant bottleneck in the development of tumor-specific diagnostic agents and theranostic drugs. Here, we show an approach to increase transendothelial permeability of macromolecular and nanoparticle-based contrast agents via inhibition of the type I TGF-β receptor, activin-like kinase 5 (Alk5), in tumors. Alk5 inhibition significantly increased tumor contrast agent delivery and enhancement on imaging studies, while healthy organs remained relatively unaffected. Imaging data correlated with significantly decreased tumor interstitial fluid pressure, while tumor vascular density remained unchanged. This immediately clinically translatable concept involving Alk5 inhibitor pretreatment prior to an imaging study could be leveraged for improved tumor delivery of macromolecular and nanoparticle-based imaging probes and, thereby, facilitate development of more sensitive imaging tests for cancer diagnosis, enhanced tumor characterization, and personalized, image-guided therapies.

Identifiers

PMID27182558
PMCPMC4864003
OpenAlexW2347010102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.